

Prof. BÜLENT YALÇIN



Personal Information

Email: b.yalcin@aybu.edu.tr

Web: <https://avesis.aybu.edu.tr/byalcin>

International Researcher IDs

ScholarID: e62M74AAAAJ

ORCID: 0000-0002-4431-8948

Publons / Web Of Science ResearcherID: HIK-0062-2022

ScopusID: 9637671400

Yoksis Researcher ID: 182357

Biography

Ankara Üniversitesi Tıp Fakültesinden 1990 yılında mezun olmuştur. İç hastalıkları ve tıbbi onkoloji yan dal uzmanlıklarını Ankara Üniversitesi Tıp Fakültesinden, sırasıyla 1995 ve 1999 yılında almıştır.

Education Information

Post Doctorate of Medicine, Ankara University, Ankara Tıp Fakültesi, Turkey 1997 - 2000

Research Areas

Medicine

Academic Titles / Tasks

Associate Professor, Ankara University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2006 - Continues

Academic and Administrative Experience

Ankara Yıldırım Beyazıt Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2011 - Continues

Published journal articles indexed by SCI, SSCI, and AHCI

- Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment**
Bardakci M., Karakas H., Bayram D., Avci N., Kitaplı S., Ozen M., Aslan F., Koseoglu C., Kadioglu A., Onur I. D., et al.
Scientific Reports, vol.14, no.1, 2024 (SCI-Expanded)
- Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter study**
Sekmek S., Karahan I., Ucar G., Ceylan F., Bayram D., Seven I., Bölek H., Ürün Y., Yücel K. B., Yazıcı O., et al.

Clinical and Translational Oncology, vol.26, no.8, pp.1878-1885, 2024 (SCI-Expanded)

- III. **A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review**
Efil S. C., Bilgin B., Ceylan F., Karakaş H., Karahan İ., Özsan S. N., Kosku H., Yaman Ş., Bülent Akıncı M., Dede D., et al.
Journal of Oncology Pharmacy Practice, 2024 (SCI-Expanded)
- IV. **The diurnal change of thyroid-stimulating hormone and the effect of this change on thyroid functions in patients with chronic kidney disease**
Soylu H., Ersoy R., Keske P. B., Tunçay M. E., Ateş C., Çakır B., Yalçın B.
Endocrine, vol.82, no.3, pp.580-585, 2023 (SCI-Expanded)
- V. **The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)**
Hızal M., Bilgin B., Paksoy N., Atıcı M. M., KAHRAMAN S., Kılıçkap S., Güven D. C., KESKİNKILIÇ M., Ayhan M., Eren Ö., et al.
Journal of Cancer Research and Clinical Oncology, vol.149, no.8, pp.4141-4148, 2023 (SCI-Expanded)
- VI. **Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer**
Chi K. N., Rathkopf D., Smith M. R., Efstathiou E., Olmos D., Lee J. Y., Small E. J., Pereira De Santana Gomes A. J., Saad M., Mason G. E., et al.
Journal of Clinical Oncology, vol.41, no.18, pp.3339-3351, 2023 (SCI-Expanded)
- VII. **Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer**
KAHRAMAN S., Erul E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., Acar O., AKSOY S., Baytemur N. K., ŞAHİN E., et al.
Future Oncology, vol.19, no.10, pp.727-736, 2023 (SCI-Expanded)
- VIII. **Tamoxifen related chorioretinal structural changes**
Erbahçeci Timur İ. E., Açıkgöz V., Uğurlu N., Yalçın B., ŞENDUR M. A. N., Hızal M., KARA H.
Cutaneous and Ocular Toxicology, vol.42, no.3, pp.109-117, 2023 (SCI-Expanded)
- IX. **Do metastatic volumes measured in breast cancer patients with bone metastases correlate with the numbers of skeletal and extraskelatal events?**
Yağar H., Aytakin M. N., sener dede D., Sendur M., öztürk r., yalcin b.
Joint Diseases and Related Surgery, vol.35, no.1, pp.105-111, 2023 (SCI-Expanded)
- X. **Clinicopathological and survival features of neuroendocrine tumors: A retrospective analysis of 153 cases, our current remarks on a heterogeneous tumor group, and still unmet future expectations**
KAHRAMAN S., Bardakci M., Aykan M. B., YAŞAR S., Erol C., Hızal M., Akıncı M. B., Kos F. T., Kos T., Dede D., et al.
Journal of Cancer Research and Therapeutics, vol.19, no.2, pp.347-354, 2023 (SCI-Expanded)
- XI. **Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group**
Erol C., Nahit Sendur M. A., Bilgetekin I., Garbioglu D. B., Hamdard J., Akbas S., Hızal M., Arslan C., Sevinc A., Kucukarda A., et al.
Journal of Cancer Research and Therapeutics, vol.18, no.9, pp.347-353, 2022 (SCI-Expanded)
- XII. **An unusual infection with long-term bevacizumab treatment for advanced nonsmall-cell lung cancer: Actinomycosis**
Erol C., Nahit Sendur M. A., YALÇIN B.
Journal of cancer research and therapeutics, vol.18, no.6, pp.1809-1810, 2022 (SCI-Expanded)
- XIII. **The relationship between adjuvant chemotherapy and thiol-disulfide compounds**
Akyol P., Dede D., Bilgin B., Ulaş A., Nahit Şendur M. A., AKINCI M. B., BAŞER S., EROL C., HIZAL M., YALÇIN B.
Journal of Cancer Research and Therapeutics, vol.18, no.4, pp.1114-1118, 2022 (SCI-Expanded)
- XIV. **The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study**
Hızal M., Bilgin B., Paksoy N., Açıkgöz Ö., Sezer A., Gürbüz M., Ak N., Yücel Ş., Ayhan M., EROL C., et al.
Journal of Cancer Research and Clinical Oncology, vol.148, no.6, pp.1501-1508, 2022 (SCI-Expanded)
- XV. **Cutaneous Metastasis from Transitional Cell Carcinoma of Urinary Bladder**

KALKAN G., Ahsen H., YALÇIN B.

Journal of the College of Physicians and Surgeons Pakistan, vol.32, no.6, 2022 (SCI-Expanded)

- XVI. **Who should be treated with pembrolizumab in addition to standard of care in advanced cervical cancer?**
KAHRAMAN S., Erbas U. E., YALÇIN B.
Medical Oncology, vol.39, no.3, 2022 (SCI-Expanded)
- XVII. **Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)**
Erol C., Sakin A., Başoğlu T., Özden E., ÇABUK D., Doğan M., Öksüzöğlü B., YILDIRIM H. Ç., Öner İ., Karakurt Eryılmaz M., et al.
Turkish Journal of Medical Sciences, vol.52, no.4, pp.1022-1032, 2022 (SCI-Expanded)
- XVIII. **The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement**
Bilgin B., ŞENDUR M. A. N., Yücel Ş., Hizal M., Güner G., Akyürek N., EROL C., AKINCI M. B., Dede D., YALÇIN B., et al.
Journal of Cancer Research and Clinical Oncology, vol.147, no.9, pp.2637-2643, 2021 (SCI-Expanded)
- XIX. **Can the host immune response against SARS-CoV2 also cause an anticancer effect?**
KAHRAMAN S., AKINCI M. B., ŞENDUR M. A. N., YALÇIN B.
Medical Oncology, vol.38, no.8, 2021 (SCI-Expanded)
- XX. **Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study**
Bilgin B., ŞENDUR M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., Basoglu T., Ilhan A., Akdeniz N., Gulmez A., et al.
Journal of Cancer Research and Clinical Oncology, vol.147, no.7, pp.2145-2152, 2021 (SCI-Expanded)
- XXI. **Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data**
Ates O., Oksuzoglu O. B., Aktas B. Y., Karadag I., Esen S., Karakaya S., Uncu D., Erol C., Gurbuz M., YALÇIN B., et al.
Journal of B.U.ON., vol.26, no.4, pp.1398-1404, 2021 (SCI-Expanded)
- XXII. **Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)**
Hizal M., Sendur M. A., Yasar H. A., Bir Yucel K., Arslan C., Ucar G., Karakaya S., Taban H., Kucukarda A., Erturk I., et al.
Journal of Oncology Pharmacy Practice, vol.26, no.7, pp.1583-1589, 2020 (SCI-Expanded)
- XXIII. **Atezolizumab and Bevacizumab in Hepatocellular Carcinoma**
Hizal M., Sendur M. A. N., YALÇIN B.
The New England journal of medicine, vol.383, no.7, pp.694, 2020 (SCI-Expanded)
- XXIV. **A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint**
HIZAL M., ŞENDUR M. A. N., BİLGİN B., AKINCI M. B., ŞENER DEDE D., YALÇIN B.
Current Medical Research and Opinion, vol.36, no.4, pp.625-635, 2020 (SCI-Expanded)
- XXV. **Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?**
Yaman S., Bilgin B., Sendur M. A. N., Hizal M., Akinci M. B., Yalcin B.
FUTURE ONCOLOGY, vol.15, no.9, pp.925-927, 2019 (SCI-Expanded)
- XXVI. **Prognostic effect of red cell distribution width-to-platelet ratio in colorectal cancer according to tumor stage and localization**
Bilgin B., Sendur M. A. N., Hizal M., Dede D., Akinci M. B., Kandil S. U., Yaman S., Yalcin A., Kilic M., Yalcin B.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.15, no.1, pp.54-60, 2019 (SCI-Expanded)
- XXVII. **The results of nasopharyngeal cancer patients treated by simultaneous integrated boost technique and concomitant chemotherapy**
Cetindag M. F., Ozsavran A. Y., Yalcin B., Cetindag I., Ercan K., TÜRKÖLMEZ Ş., Yegen D.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.2, pp.558-565, 2019 (SCI-Expanded)
- XXVIII. **Expanding treatment options for resectable gastric cancer: Is it a countdown for radiotherapy?**

- HIZAL M., ŞENDUR M. A. N., BİLGİN B., AKINCI M. B., Dede D., YALÇIN B.
Journal of B.U.ON., vol.24, no.4, pp.1367-1370, 2019 (SCI-Expanded)
- XXIX. **Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.**
Dogan H. T., Kiran M., Bilgin B., Kilicarslan A., Sendur M. A. N., Yalcin B., Ardicoglu A., Atmaca A. F., Gumuskaya B.
Diagnostic pathology, vol.13, pp.60, 2018 (SCI-Expanded)
- XXX. **Comparison of gemcitabine monotherapy with gemcitabine and cisplatin combination in metastatic pancreatic cancer: a retrospective analysis**
Ergun Y., Ozdemir N. Y., Guner E. K., Esin E., ŞENDUR M. A. N., Koksoy E. B., Demirci N. S., Eren T., Dede I., Sezer A., et al.
JOURNAL OF BUON, vol.23, 2018 (SCI-Expanded)
- XXXI. **The current status of adjuvant treatment for high-risk renal cell carcinoma**
HIZAL M., ŞENDUR M. A. N., Bilgin B., AKINCI M. B., ŞENER DEDE D., YALÇIN B.
FUTURE ONCOLOGY, vol.13, no.23, pp.2017-2020, 2017 (SCI-Expanded)
- XXXII. **Comparison of Clinicopathologic Parameters and Survivals Between Epstein-Barr Virus-positive and Her2-positive Gastric Cancers**
Irkkan C., Balci S., Tezel G. G., Akinci B., Yalcin B., Guler G.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, vol.25, no.9, pp.609-614, 2017 (SCI-Expanded)
- XXXIII. **Adjuvant Capecitabine for Breast Cancer**
Hizal M., Sendur M. A. N., Yalcin B.
NEW ENGLAND JOURNAL OF MEDICINE, vol.377, no.8, pp.791, 2017 (SCI-Expanded)
- XXXIV. **The significance of serum leptin level in patients with early stage nonsmall cell lung cancer**
Karatas F., YALÇIN B., Sahin S., AKBULUT H., Utkan G., DEMİRKAZIK A., İÇLİ F.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.13, no.2, pp.204-207, 2017 (SCI-Expanded)
- XXXV. **Chemotherapy in primary osteogenic sarcoma in patients over the age of forty**
Ozkurt B., Basarir K., YALÇIN B., MERTER A., YILDIZ Y., Saglik Y.
Acta Orthopaedica et Traumatologica Turcica, vol.51, no.2, pp.123-127, 2017 (SCI-Expanded)
- XXXVI. **A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer**
Bilgin B., Sendur M. A. N., Dede D. S., Akinci M. B., Yalcin B.
CURRENT MEDICAL RESEARCH AND OPINION, vol.33, no.9, pp.1559-1569, 2017 (SCI-Expanded)
- XXXVII. **Adding Chemotherapy After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer; Promising or not?**
ŞENDUR M. A. N., BİLGİN B., AKSOY S., Akinci B., ÖZDEMİR N., Dede D. S., YALÇIN B., Zengin N.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.27, no.3, pp.194-196, 2017 (SCI-Expanded)
- XXXVIII. **Syringocystadenoma papilliferum with multiple lung metastases and long survival**
Ozdemir B., Sendur M. A. N., Comert P., Yalcin B.
JOURNAL OF BUON, vol.21, no.5, pp.1324-1325, 2016 (SCI-Expanded)
- XXXIX. **Occult urinary incontinence in elderly women and its association with geriatric condition**
Silay K., Akinci S., Ulas A., Yalcin A., Silay Y. S., Akinci M. B., Dilek I., Yalcin B.
European Review for Medical and Pharmacological Sciences, vol.20, no.3, pp.447-451, 2016 (SCI-Expanded)
- XL. **Thrombotic thrombocytopenic purpura following salvage chemotherapy with paclitaxel, ifosfamide and cisplatin in a patient with a refractory germ cell tumor: A case report and review of the literature**
Ulas A., SILAY K., Akinci S., AKINCI M. B., ŞENDUR M. A. N., ŞENER DEDE D., POLAT Y. H., YALÇIN B.
ONCOLOGY LETTERS, vol.10, no.4, pp.2223-2226, 2015 (SCI-Expanded)
- XLI. **Radiotherapy concurrent with weekly gemcitabine after transurethral tumor resection in muscle invasive bladder cancer**
Demirci U., Dizdar O., Cetindag M. F., Altinova S., Ozsavran A., Dede D., Kizilirmak N., Eraslan F. A., YALÇIN B., Cinkir

H. Y.

Journal of Cancer Research and Therapeutics, vol.11, no.4, pp.704-707, 2015 (SCI-Expanded)

- XLII. **Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers**
Baykara M., Benekli M., EKİNCİ Ö., Irkkan S. C., Karaca H., Demirci U., AKINCI M. B., Unal O. U., DANE F., Turkoz F. P., et al.
JOURNAL OF GASTROINTESTINAL SURGERY, vol.19, no.9, pp.1565-1571, 2015 (SCI-Expanded)
- XLIII. **Do Statins Really Improve Colorectal Cancer-Specific Mortality?**
ŞENDUR M. A. N., AKSOY S., Yalcin B.
JOURNAL OF CLINICAL ONCOLOGY, vol.33, no.7, pp.811, 2015 (SCI-Expanded)
- XLIV. **Denosumab: Excellent response of metastatic giant cell tumor of the bone**
Ulas A., Akinci M. B., Silay K., Sendur M. A. N., Dede D., Yalcin B.
Journal of B.U.ON., vol.20, no.2, pp.666-667, 2015 (SCI-Expanded)
- XLV. **The myth of not disclosing the diagnosis of cancer: Does it really protect elderly patients from depression?**
SILAY K., Akinci S., Ulas A., Silay Y. S., AKINCI M. B., Ozturk E., Canbaz M., DİLEK İ., YALÇIN B.
Asian Pacific Journal of Cancer Prevention, vol.16, no.2, pp.837-840, 2015 (SCI-Expanded)
- XLVI. **Primary chest wall angiosarcoma**
Kabalak P. A., Demir N., YALÇIN B., CEYHAN K., KARNAK D.
Turkish Journal of Thoracic and Cardiovascular Surgery, vol.23, no.4, pp.766-769, 2015 (SCI-Expanded)
- XLVII. **Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer**
ŞENDUR M. A. N., AKSOY S., AKINCI M. B., Ozdemir N., ŞENER DEDE D., Altundag K., Zengin N., YALÇIN B.
FUTURE ONCOLOGY, vol.11, no.6, pp.905-907, 2015 (SCI-Expanded)
- XLVIII. **Actual benefit of chemo-hormonal therapy in non-castrate metastatic prostate cancer**
ŞENDUR M. A. N., AKINCI M. B., Ozdemir N. Y., AKSOY S., ŞENER DEDE D., Ulas A., Zengin N., YALÇIN B.
FUTURE ONCOLOGY, vol.11, no.8, pp.1141-1143, 2015 (SCI-Expanded)
- XLIX. **Opinions of the Turkish population on cancer and being informed of the diagnosis of cancer**
YALÇIN A., SILAY K., Buyukcelik A., Isikdogan A., TÜRK H. M., COŞKUN H. Ş., ÖZDEMİR F., UĞURLU M., ÜSTÜ Y., YALÇIN B.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.45, no.2, pp.387-392, 2015 (SCI-Expanded)
- L. **Hospitalization risk according to geriatric assessment and laboratory parameters in elderly hematologic cancer patients**
SILAY K., Akinci S., Silay Y. S., Guney T., Ulas A., AKINCI M. B., Ozturk E., Canbaz M., YALÇIN B., DİLEK İ.
Asian Pacific Journal of Cancer Prevention, vol.16, no.2, pp.783-786, 2015 (SCI-Expanded)
- LI. **Resistance to Androgen-Pathway Drugs in Prostate Cancer**
ŞENDUR M. A. N., AKINCI M. B., YALÇIN B.
NEW ENGLAND JOURNAL OF MEDICINE, vol.371, no.23, pp.2233, 2014 (SCI-Expanded)
- LII. **End-of-study results of Turkish gastric cancer patients from the global REGATE study**
YALÇIN Ş., Gumus M., KILIÇKAP S., Alkis N., Ilhan M., Oksuzoglu B., Orhan B., Unsal M., TEKİN S. B., Yalcin B., et al.
JOURNAL OF BUON, vol.19, no.2, pp.377-387, 2014 (SCI-Expanded)
- LIII. **Substance P is a major mediator causing delayed emesis in anthracycline-based chemotherapy - Really?**
Ulas A., Silay K., Akinci S., Yalcin B.
Asian Pacific Journal of Cancer Prevention, vol.15, no.24, pp.10993, 2014 (SCI-Expanded)
- LIV. **The relationship between common EGFR, BRAF, KRAS mutations and prognosis in advanced stage non-small cell lung cancer with response to the treatment in Turkey Türkiye'de İleri evre küçük hücreli akciğer kanserinde görülen EGFR, BRAF, KRAS mutasyonlarıni tedaviye yani ve prognozla ilişkisi**
Dogan M., Demirkazik A., Tukun A., SAK S., CEYHAN K., YALÇIN B., AKBULUT H., Icli F.
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.24, no.1, pp.1-10, 2014 (SCI-Expanded)
- LV. **Expectations of Response from Octreotide Therapy in Recurrent Phosphaturic Mesenchymal Tumors**

- Do They Reflect Reality?

Ulas A., Dede D., Sendur M. A. N., Akinci M. B., Yalcin B.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.24, pp.10997-10998, 2014 (SCI-Expanded)

- LVI. **Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study**
Ozdemir N., Abali H., Vural M., YALÇIN Ş., Oksuzoglu B., Civelek B., Oguz D., Bostanci B., YALÇIN B., ZENGİN N.
Cancer Chemotherapy and Pharmacology, vol.74, no.6, pp.1139-1147, 2014 (SCI-Expanded)
- LVII. **Intraabdominal follicular dendritic cell sarcoma: A report of three cases and review of the literature**
ÜRÜN Y., ENNELİ D., Koral L., YALÇIN B., KIRMIZI B. A., CEYHAN K., Boruban M. C., UTKAN G., Demirkazik A.
Tumori, vol.99, no.2, 2013 (SCI-Expanded)
- LVIII. **Non-metastatic upper tract transitional cell carcinoma: Single center experience**
Demirci U., Canda A. E., Dede D., Cakici O. U., AKINCI M. B., Yalcin B.
Asian Pacific Journal of Cancer Prevention, vol.14, no.2, pp.1131-1132, 2013 (SCI-Expanded)
- LIX. **Malign peritoneal mesothelioma with nephrotic syndrome**
DOĞAN M. E., Ozal G., SAVAŞ B., Gungor M., UTKAN G., YALÇIN B., Icli F.
Bratislava Medical Journal, vol.113, no.1, pp.43-45, 2012 (SCI-Expanded)
- LX. **Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature**
Dogan M., YALÇIN B., Ozdemir N. Y., Arslan U. Y., Dogan L., UTKAN G., AKBULUT H., ZENGİN N., Alkis N., Icli F.
Medical Oncology, vol.29, no.3, pp.2021-2026, 2012 (SCI-Expanded)
- LXI. **The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis**
Bozcuk H., Abali H., Coskun S., Aydinler A., Çinkaya A., Demirkazik A., Özet A., Yolcu A., Balkan A., Çavdar A., et al.
World Journal of Surgical Oncology, vol.10, 2012 (SCI-Expanded)
- LXII. **ABO and Rh blood groups frequency in women with HER2 positive breast cancer**
Urun Y., Utkan G., Altundag K., Arslan O., Onur H., Arslan U. Y., Kocer M., Dogan I., Senler F. C., Yalcin B., et al.
JOURNAL OF BUON, vol.17, no.3, pp.457-460, 2012 (SCI-Expanded)
- LXIII. **An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy**
Grünwald V., Karakiewicz P. I., Bavbek S. E., Miller K., Lee S., Larkin J., Rha S. Y., Castellano D., Blank C. U., Knox J. J., et al.
European Journal of Cancer, vol.48, no.3, pp.324-332, 2012 (SCI-Expanded)
- LXIV. **ABO and Rh Blood Groups and Risk of Colorectal Adenocarcinoma**
ÜRÜN Y., Ozdemir N. Y., Utkan G., AKBULUT H., SAVAŞ B., Oksuzoglu B., ÖZTUNA D., Dogan I., Yalcin B., ŞENLER F. Ç., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.12, pp.6097-6100, 2012 (SCI-Expanded)
- LXV. **Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients**
Dogan M., KARABULUT H. G., Tukun A., Demirkazik A., UTKAN G., YALÇIN B., Dincol D., AKBULUT H., Icli F.
Asian Pacific Journal of Cancer Prevention, vol.13, no.4, pp.1553-1556, 2012 (SCI-Expanded)
- LXVI. **Albumin Infusion is not Beneficial in Hypoalbuminemic End-Stage Cancer Patients: A Matched-Pair Analysis**
Buyukcelik A., DEMİRKAZIK A., YALÇIN B., Dogan M., KAVGACI H., Coban S., İÇLİ F.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGISİ, vol.22, no.4, pp.213-219, 2012 (SCI-Expanded)
- LXVII. **The role of preoperative serum thyroglobulin and thyroid auto-antibody levels before histopathological diagnosis of thyroid cancers Tiroid kanserlerinin histopatolojik tanı öncesinde serum tiroglobülin ve tiroid oto-antikorları seviyelerinin rolü**
Yalcin S., Ülger B. V., Parlak Ö., Uçar A. E., Sarikaya S. M., Özer M., Korukluoğlu B., YALÇIN B., Kuşdemir A.
Turkish Journal of Medical Sciences, vol.41, no.3, pp.487-493, 2011 (SCI-Expanded)
- LXVIII. **Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10**

years follow-up)

Icli F., AKBULUT H., Onur H., YALÇIN B., Demirkazık A., Şenler F. Ç.
Breast, vol.20, no.2, pp.155-157, 2011 (SCI-Expanded)

LXIX. Extranodal Hodgkin disease presenting with gluteal mass and hypercalcemia [9]

UTKAN G., Buyukcelik A., YALÇIN B., Tek I., Doruk H., Dincol D., Erekuş S., Baykara M.
Southern Medical Journal, vol.99, no.10, pp.1149-1150, 2006 (SCI-Expanded)

LXX. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.

YALÇIN B., Pamir A., Büyükçelik A., UTKAN G., AKBULUT H., DEMİRKAZIK A., İÇLİ F.
experimental oncology, vol.26, no.4, pp.20-25, 2004 (SCI-Expanded)

Articles Published in Other Journals

- I. **Association of Inflammatory Markers with Treatment Response in Immune Checkpoint Inhibitors**
Bardakçı M., Bal Ö., Köş F. T., Demirtaş Esmir D., Hafizoğlu E., Karakaş H., AKINCI M. B., Yalçin B.
Journal of Oncological Science, vol.9, no.3, pp.158-165, 2023 (Scopus)
- II. **Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience**
EROL C., Bardakçı M., Hizal M., KAHRAMAN S., Yekedüz E., Güven D. C., Aykan M. B., Ak R., Ateş Ö., ŞENER DEDE D., et al.
Journal of Oncological Science, vol.9, no.2, pp.72-78, 2023 (Scopus)
- III. **The Real-Life Efficacy of the Second Line Treatment Strategy in Advanced Pancreas Cancer**
Hizal M., ŞENDUR M. A. N., Bilgin B., Karci Güner E., AKINCI M. B., Ergün Y., Esin E., KÖKSOY E. B., Sezer A., ÖZDEMİR N., et al.
Journal of Oncological Science, vol.8, no.2, pp.69-75, 2022 (Scopus)
- IV. **Clinical features of the ALK-mutant non-small cell lung cancer patients who received first-line alectinib treatment Birinci basamak alektinib tedavisi alan alk mutasyonu pozitif akciğer kanseri hastalarının klinik özelliklerinin değerlendirilmesi**
Hizal M., Bilgin B., Şendur M. A., Yücel Ş., KAHRAMAN S., EROL C., Akinci B., ŞENER DEDE D., Algin E., YALÇIN B.
Tuberkuloz ve Toraks, vol.69, no.3, pp.321-327, 2021 (ESCI)
- V. **The relationship between vitamin d level and disease activity in patients with rheumatoid arthritis**
AKDAĞ G., ERTEN Ş., AKAN S., yanık üstüner g., KÜÇÜKŞAHİN O., YEŞİL T. H., YALÇIN B.
ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, vol.11, 2020 (ESCI)
- VI. **The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer Küçük hücreli dışı akciğer kanserinde yüksek pd-11 düzeyi ile ilişkili klinikopatolojik faktörlerin ve periferik kan parametrelerinin belirlenmesi**
Bilgin B., HIZAL M., Yücel Ş., ŞENDUR M. A. N., AKYÜREK N., AKINCI M. B., Yılmaz Ü., YALÇIN B.
Tuberkuloz ve Toraks, vol.68, no.2, pp.118-125, 2020 (ESCI)
- VII. **Prognostic importance of Albumin globulin ratio in small cell lung cancer Albümin Globulin Oraninin Küçük Hücreli Akciğer Kanserinde Prognostik Önemi**
BİLGİN B., ŞENDUR M. A. N., yücel Ş., HIZAL M., YALÇIN B.
Ankara Medical Journal, vol.18, no.4, pp.729-735, 2019 (Scopus)
- VIII. **Following Chemotherapy: Serum Cytokine (Tumor Necrosis Factor, Interleukin-2, Interleukin-11), Immunoglobulin, Complement, Vascular Endothelial Growth Factor Levels, and the Systemic Symptoms like Capillary Leak Syndrome**
KESKİN H., ÇADIRCI K., DEMİRKAZIK A., AKBULUT H., YALÇIN B.
Biomarkers in Cancer, vol.11, no.6, pp.1-9, 2019 (Peer-Reviewed Journal)
- IX. **Evaluation of dynamic serum thiol-disulphide homeostasis in colorectal cancer**
BİLGİN B., ŞENDUR M. A. N., HIZAL M., kandil ulutaş s., yaman s., AKINCI M. B., ŞENER DEDE D., EREL Ö., YALÇIN B.
Journal of Oncological Sciences, 2019 (Peer-Reviewed Journal)

- X. **Metastatic anal cloacogenic cell carcinoma misdiagnosed as urothelial carcinoma with long survival**
BİLGİN B., YALÇIN B., ŞENDUR M. A. N., AĞAÇKIRAN Y.
Journal of Oncological Sciences, vol.3, no.2, pp.87-88, 2017 (Peer-Reviewed Journal)
- XI. **The efficacy of tissue factor-603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients**
Eroğlu A., Ceylan G., Ozturk E., Yalcin A., Yalcin B., Karasoy D.
Experimental Oncology, vol.38, no.3, pp.187-190, 2016 (Scopus)
- XII. **Assessment of Falls in Older People Is There any Association Between Restless Leg Syndrome and Falls**
SILAY K., ÖZKAYA H., yalçın a., akıncı s., ulaş a., ÖZTÜRK E., canbaz m., YALÇIN B.
Ankara Medical Journal, vol.16, no.1, 2016 (Peer-Reviewed Journal)
- XIII. **The Efficacy of Tissue Factor 603A g and 5466A G Polimorphisms at the Development of Venous Thromboembolism in Cancer Patients**
EROĞLU A., Ceylan G. G., Öztürk E., YALÇIN A., YALÇIN B., KARASOY D.
Experimental Oncology, vol.38, pp.187-190, 2016 (Scopus)
- XIV. **Böbrek Hücreli Karsinomlu Hastaların Demografik Özellikleri ve Tedavi Sonuçları Tek Merkez Deneyimi Demographic Characteristics and Treatment Outcomes of Patients with Renal Cell Cancer Single Center Experience**
ulaş a., BİLGİN B., ŞENER DEDE D., köş t., AKINCI M. B., ŞENDUR M. A. N., YALÇIN B.
Ankara Medical Journal, 2016 (Peer-Reviewed Journal)
- XV. **An Independent Risk Factor for Quality of Life in Cancer Patients Urinary Incontinence**
SILAY K., Sema A., BAŞTÜRK A., Ulas A., Ulusoy N., Senem M., DİLEK İ., YALÇIN B.
Acta Medica Anatolia, vol.3, no.4, pp.132-136, 2015 (Peer-Reviewed Journal)
- XVI. **The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer**
ÜRÜN Y., UTKAN G., YALÇIN B., AKBULUT H., onur h., ÖZTUNA D., ÇAY ŞENLER F., DEMİRKAZIK A., İÇLİ F.
experimental oncology, vol.37, no.1, pp.53-57, 2015 (Scopus)
- XVII. **Medication errors in chemotherapy preparation and administration: A survey conducted among oncology nurses in Turkey**
Ulas A., Silay K., Akinci S., Dede D., AKINCI M. B., ŞENDUR M. A. N., Cubukcu E., COŞKUN H. Ş., Degirmenci M., UTKAN G., et al.
Asian Pacific Journal of Cancer Prevention, vol.16, no.5, pp.1699-1705, 2015 (Scopus)
- XVIII. **TÜRKİYE DE ONKOLOJİ HASTALARININ BİYOPSİKOSOSYAL VE KOZMİK İHTİYAÇLARI**
SILAY K., AKINCI M. B., ARİFE U., AKINCI S., ŞENDUR M. A. N., ŞENER DEDE D., YALÇIN B.
Turkiye Klinikleri Journal of Psychiatry Special Topics, vol.7, no.4, pp.1-4, 2014 (Peer-Reviewed Journal)
- XIX. **Staging risk assessment and screening of breast cancer**
YALÇIN B.
experimental oncology, vol.35, no.4, pp.238-245, 2013 (Scopus)
- XX. **Overview on locally advanced breast cancer defining epidemiology and overview on neoadjuvant therapy**
YALÇIN B.
experimental oncology, vol.35, no.4, pp.250-252, 2013 (Scopus)
- XXI. **Primary Thyroid Lymphoma Diagnosed During Pregnancy A Case Report**
Demir Önal E., Polat Ş. B., Korkmaz M. H., Yalçın B., Köybaşıoğlu F., Ersoy R., Çakır B.
TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM, vol.17, no.2, pp.49-51, 2013 (Scopus)
- XXII. **Levels of trace elements and toxic metals in autopsy renal tissue samples Otopsi böbrek dokusu örneklerinde iz element ve toksik metal düzeylerinin değerlendirilmesi**
Yılmaz H., TÜRKSOY V. A., Kayaalti Z., YALÇIN B., Söylemezoğlu T.
Turkiye Klinikleri Journal of Medical Sciences, vol.32, no.1, pp.7-14, 2012 (Scopus)
- XXIII. **Kikuchi - Fujimoto disease: Cervical lymphadenopathy suggestive of relapsing lymphoma in patient with lymphoblastic lymphoma**

ÜRÜN Y., UTKAN G., ENNELİ D., DOĞAN M. E., YALÇIN B., İCİ F.
Experimental Oncology, vol.33, no.4, pp.242-244, 2011 (Scopus)

- XXIV. **Two cases with atypical metastasis in colorectal cancer splenic and renal metastasis**
dogan m., ozal f. g., ikinci c., UTKAN G., ÜRÜN Y., YALÇIN B., İÇLİ F.
experimental oncology, vol.32, no.4, pp.277-279, 2010 (Scopus)
- XXV. **A metastasis of colorectal cancer to the thyroid gland which has also papillary thyroid cancer: A case report**
YALÇIN A., ÜNAL A. E., BAYAR S., YALÇIN B.
Turkish J Cancer, 2008 (Peer-Reviewed Journal)
- XXVI. **Pseudomyxoma peritonei: What Do We Have?**
YALÇIN A., ERGÜL E., KORUKLUOĞLU B., YALÇIN B.
The Internet Journal of Surgery, 2008 (Peer-Reviewed Journal)

Books & Book Chapters

- I. **İmmünoterapi ve İlaç Etkileşimleri**
HAFIZOĞLU E., YALÇIN B.
in: İMMÜNÖTERAPİLERİN YAN ETKİ YÖNETİMİ, Mehmet Ali Nahit Şendur, Editor, Türkiye Klinikleri, pp.72-77, 2022
- II. **Hepatoselüler kanserde etiopatogenez, önleme, evreleme.**
HIZAL M., AKINCI M. B., YALÇIN B.
in: Hepato-Pankreato Biliyer Sistem Kanseri, Özet A, Özdemir N, Yazıcı O, Editor, Türkiye Klinikleri, pp.10-18, 2021
- III. **Medüller Tiroid Kanserinde Hedefe Yönelik Tedaviler**
BİLGİN B., YALÇIN B.
in: TİROİD KANSERİ GÜNCEL YAKLAŞIM, Bekir Çakır, Editor, Akademisyen Kitapevi, pp.531-538, 2020
- IV. **Solunum sistemi muayenesi.**
ŞENER DEDE D., SILAY K., AKINCI M. B., ŞENDUR M. A. N., YALÇIN B., DENİZ O., ÇAKIR B., AYHAN H., AYDIN C., ARGÜDER E., et al.
in: Erişkinlerde Anamnez ve Fizik Muayene, OSMAN ERSOY, ÖYKÜ TAYFUR YÜREKLİ, MEHMET ALİ NAHİT ŞENDUR, Editor, ANKARA NOBEL TIP KİTAPEVİ, Ankara, pp.59-78, 2019

Refereed Congress / Symposium Publications in Proceedings

- I. **PROGNOSTIC AND PREDICTIVE MARKERS OF FOLFIRI/AFLIBERCEPT IN PATIENTS WITH METASTATIC COLORECTAL CANCER (TOG STUDY)**
EROL C., HIZAL M., BİLGİTEKİN İ., AKBAŞ S., GARİPOĞLU D. B., HAMDARD J., ARSLAN Ç., SEVİNÇ A., KÜÇÜKARDA A., GÜRGENYATAĞI D., et al.
10. INTERNATIONAL GASTROINTESTINAL CANCER CONFERENCE, Turkey, 2 - 06 December 2020, pp.40-41
- II. **EFFICACY AND SAFETY OF FOLFIRI/AFLIBERCEPT IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS (TOG STUDY)**
EROL C., HIZAL M., BİLGİTEKİN İ., AKBAŞ S., ŞENER DEDE D., AKINCI M. B., YALÇIN B., ÇİÇİN İ., ŞENDUR M. A. N., ARTAÇ M., et al.
10TH International Gastrointestinal Cancers Virtual Conference, Online, Turkey, 2 - 06 December 2020, pp.39-40
- III. **PROGNOSTIC AND PREDICTIVE MARKERS OF FOLFIRI/AFLIBERCEPT IN PATIENTS WITH METASTATIC COLORECTAL CANCER (TOG STUDY)** Cihan Erol¹, Mutlu Hızal², Irem Bilgetekin³, Sinem Akbas⁴, Duygu Bayir Garbioglu⁵, Jamshid Hamdard⁶, Çagatay Arslan⁷, Alper Sevinc⁸, Ahmet Kucukarda⁹, Dilek Gurgenyatagi¹⁰, Emre Cakir¹¹, Aykut Demirkiran¹², Murat Araz¹², Sercan On¹³, Izzet Dogan¹⁴, Atike Pinar Erdogan¹⁵, Sinan Koca¹⁶, Pinar Kubilay¹⁷, Onder Eren¹⁸, Deniz Tataroglu Ozyukseler¹⁹, Mahmut Emre Yildirim¹⁹, Ebru Cilbir²⁰, Emir Celik²¹, Aykut

Bahceci²², Halil Taskaynatan²³, Abdulkerim Oyman²⁴, Gulhan Ipek Deniz²⁵, Serkan Menenekse²⁶, Engin Kut²⁶, Ahmet Gulmez²⁷, Abdullah Sakin²⁸, Erdinc Nayir²⁹, Ramazan Acar³⁰, Seda Kahraman¹, Erdem Sen³¹, Ali Inal³², Serdar Turhal³³, Ali Osman Kaya³⁴, Semra Paydas³⁵, Didem Tastekin¹⁴, Ilhan Hacibekiroglu¹¹, Irfan Cicin⁹, Ahmet Bilici⁶, Didem Sener Dede¹, Muhammed Bulent Akinci¹, Nil Molinas Mandel³⁶, Berna Oksuzoglu³, Dogan Uncu², Bulent Yalcin¹, Mehmet Artac¹², Mehmet Ali Nahit Sendur¹

EROL C., HIZAL M., BİLGİTEKİN İ., akbaş s., ÇİÇİN İ., ŞENER DEDE D., AKINCI M. B., YALÇIN B., ŞENDUR M. A. N.
10TH International Gastrointestinal Cancers Virtual Conference, Turkey, 02 December 2020

IV. **THE INCIDENCE AND PROGNOSTIC SIGNIFICANCE OF SARCOPENIA IN ADVANCED GASTRIC CANCER PATIENTS**

GÜMÜŞÇUBUK O., HIZAL M., BİLGİN B., AKINCI M. B., YALÇIN B., ŞENER DEDE D., ŞENDUR M. A. N.
10TH International Gastrointestinal Cancers Virtual Conference, Turkey, 02 December 2020

V. **The incidence and prognostic significance of sarcopenia in advanced gastric cancer patients**

GÜMÜŞÇUBUK O., HIZAL M., BİLGİN B., AKINCI M. B., YALÇIN B., ŞENER DEDE D., ŞENDUR M. A. N.
10th International Gastrointestinal Cancer Conference, 2-6 December 2020., Turkey, 2 - 06 December 2020

VI. **The investigation of the related factors that affected targeted therapy outcome in metastatic colon cancer**

TUTUM Ş., BİLGİN B., HIZAL M., AKINCI M. B., YALÇIN B., ŞENDUR M. A. N.
10th International Gastrointestinal Cancer Conference, 2-6 December 2020., Turkey, 02 December 2020

VII. **MALİGN GLİAL TÜMÖRLERİN KLİNİKOPATOLOJİK ÖZELLİKLERİ VE SAĞKALIM VERİLERİNİN İNCELENMESİ**

Aşan B., TATLI DOĞAN H., ERCAN K., BAŞER S., ŞENDUR M. A. N., AKINCI M. B., ASAN Ö., YALÇIN B., ŞENER DEDE D.
4th International Hippocrates Congress on Medical and Health Science, Turkey, 25 - 16 September 2020

VIII. **Malign Glial Tümörlerin Klinikopatolojik Özellikleri ve Sağkalım Verilerinin İncelenmesi**

asan f. b., TATLI DOĞAN H., ERCAN K., BAŞER S., ŞENDUR M. A. N., AKINCI M. B., ASAN Ö., YALÇIN B., ŞENER DEDE D.

4. Uluslararası Hipokrat Tıp ve Sağlık Bilimleri Kongresi 25-26 Eylül 2020 Antalya, Türkiye, Antalya, Turkey, 25 September 2020, pp.925-932

IX. **Determination of the Prognostic Markers Before Second line Treatment in Metastatic Pancreas Cancer**

BİLGİN B., ŞENDUR M. A. N., KARCI GÜNER E., HIZAL M., ERGÜN Y., ESİN E., KÖKSOY E. B., AKINCI M. B., SEZER A., ÖZDEMİR N., et al.

8th International Gastrointestinal Cancer Conference, İstanbul, Turkey, 7 - 09 December 2018

X. **Efficacy of The Second-line Treatment in Metastatic Pancreas Cancer**

ŞENDUR M. A. N., BİLGİN B., KARCI GÜNER E., HIZAL M., ERGÜN Y., ESİN E., KÖKSOY E. B., SEZER A., AKINCI M. B., ÖZDEMİR N., et al.

8th International Gastrointestinal Cancer Conference, İstanbul, Turkey, 7 - 09 December 2018

XI. **The Effect of Sarcopenia on Acute Chemotherapy Toxicity in Gastrointestinal Cancer Patients Undergoing Systemic Therapy**

ÖZDEMİR N., ŞENDUR M. A. N., ZENGİN N., YALÇIN B., ŞENER DEDE D., Yazıcı O., uçar g., eren t., SILAY K., baykal a.
ESMO 2018 Congress, 19 - 23 October 2018

XII. **The effect of sarcopenia on acute chemotherapy toxicity in gastrointestinal cancer patients undergoing systemic therapy**

ÖZDEMİR N., YAZICI O., SILAY K., uçar g., eren t., ŞENER DEDE D., ŞENDUR M. A. N., AKINCI M. B., ZENGİN N., baykal a., et al.

esmo 2018, 19 - 23 October 2018

XIII. **Metastatik Pankreas Kanserinde 1. Basamakta Gemsitabin ile Gemsitabin ve Sisplatin Kombinasyonunun Karşılaştırması: Çok Merkezli Retrospektif Analiz**

ERGÜN Y., ÖZDEMİR N., KARCI GÜNER E., ESİN E., ŞENDUR M. A. N., KÖKSOY E. B., DEMİRCİ N. S., DEDE İ., SEZER A., ENGİN H., et al.

Sağlık Bilimleri Üniversitesi İç Hastalıkları Kongresi, İstanbul, Turkey, 27 - 30 June 2018

- XIV. **Independent prognostic value of inflammation in metastatic pancreatic cancer.**
ESİN E., ÇAKMAK ÖKSÜZOĞLU Ö. B., KÖKSOY E. B., DEMİRCİ N. S., ŞENDUR M. A. N., DEDE İ., SEZER A., KARCI E., ÖZDEMİR N., YALÇIN B., et al.
JOURNAL OF CLINICAL ONCOLOGY, 1 - 05 June 2018, vol.36
- XV. **Bilateral adrenalectomy for occult ectopic Cushing's syndrome in twopatients with catastrophic hypercortisolism**
TOPALOĞLU O., beştepe n., YALÇIN B., KILIÇ M., rusen metin m., UÇMAK G., ERSOY R., ÇAKIR B.
european congress of endocrinology, 19 - 22 May 2018
- XVI. **Metastatik Pankreas Kanserinde İkinci Basamak Tedavi Öncesi Prognostik Belirteçlerin Saptanması**
BİLGİN B., ŞENDUR M. A. N., KARCI GÜNER E., ERGÜN Y., ESİN E., KÖKSOY E. B., SEZER A., ÖZDEMİR N., ÇAKMAK ÖKSÜZOĞLU Ö. B., YALÇIN B., et al.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018
- XVII. **Metastatik Pankreas Kanserinde 2. Basamak Tedavilerin Etkinliği**
ŞENDUR M. A. N., BİLGİN B., KARCI GÜNER E., ERGÜN Y., ESİN E., KÖKSOY E. B., SEZER A., ÖZDEMİR N., ÇAKMAK ÖKSÜZOĞLU Ö. B., YALÇIN B., et al.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018
- XVIII. **Pankreas Kanseri ve ABO Kan Grubu İlişkisi: Çok Merkezli, Gözlemsel, Vaka-Kontrol Çalışması**
KÖKSOY E. B., UTKAN G., ERGÜN Y., ESİN E., ŞENDUR M. A. N., KARCI GÜNER E., DEDE İ., DEMİRCİ N. S., SEZER A., ENGİN H., et al.
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018
- XIX. **The Role of Dynamic Serum Thiol-Disulphide Homeostasis in Metastatic Gastric Cancer**
BİLGİN B., ŞENDUR M. A. N., HIZAL M., AKINCI M. B., DEDE D. Ş., YAMAN S., NEŞELİOĞLU S., ÖZDEMİR N., EREL Ö., YALÇIN B.
7TH INTERNATIONAL GASTROINTESTINAL CANCERS CONFERENCE, İstanbul, Turkey, 15 - 17 December 2017
- XX. **Evaluation of dynamic serum thiol disulphide homeostasis in colorectal cancer**
BİLGİN B., ŞENDUR M. A. N., HIZAL M., AKINCI M. B., ŞENER DEDE D., Yaman S., NEŞELİOĞLU S., ÖZDEMİR N., EREL Ö., YALÇIN B.
7th International Gastrointestinal Cancers Conference, 15 - 17 December 2017
- XXI. **İleri yaş gastroenteropatik nöroendokrin tümörlerde sağkalımda etkili faktörler**
TAHTACI M., kılıç g. s., POLAT Y. H., TATLI DOĞAN H., METİN M. R., TÜRKÖLMEZ Ş., KILIÇ M., YALÇIN B., ERSOY R., ERSOY O.
34.ulusal gastroenteroloji haftası, Turkey, 1 - 06 December 2017
- XXII. **İleri yaş gastroenteropankreatik nöroendokrin tümörlerde sağkalımda etkili faktörler (Ankara Yıldırım Beyazıt Üniversitesi GEP-NET grup)**
TAHTACI M., KILIÇ G. S., POLAT Y. H., TATLI DOĞAN H., RUSEN METİN M., TÜRKÖLMEZ Ş., KILIÇ M., YALÇIN B., ERSOY R., ERSOY O.
34. ULUSAL GASTROENTEROLOJİ HAFTASI, Turkey, 1 - 06 December 2017
- XXIII. **İleri yaş gastroenteropankreatik tümörlerde sağkalımda etkili faktörler (Ankara Yıldırım Beyazıt Üniversitesi GEP-NET grup)**
TAHTACI M., kılıç G. s., POLAT Y. H., metin rusen m., TATLI DOĞAN H., TÜRKÖLMEZ Ş., KILIÇ M., YALÇIN B., ERSOY R., ERSOY O.
34.ulusal gastroenteroloji haftası, Turkey, 1 - 06 December 2017
- XXIV. **The association and prognostic significance of programmed death-ligand 1 (PD-L1) and isocitrate dehydrogenase (IDH-1) mutation in glioblastoma multiforme (GBM) patients.**
ŞENER DEDE D., TATLI DOĞAN H., Asan F. B., GÜMÜŞKAYA ÖCAL B., Ayık S., ŞENDUR M. A. N., Arife U., BİLGİN B., HIZAL M., AKINCI M. B., et al.
2017 ASCO Annual Meeting, J Clin Oncol 35, 2017 (suppl abstr e13536), 2 - 06 June 2017
- XXV. **Panhipopitüitarizmin nadir bir nedeni: meme kanseri metastazı**
ÖZDEMİR D., BİLGİN M. C., AKINCI M. B., YALÇIN B., KARAKÖK E., ERSOY R., ÇAKIR B.
39. Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi, Turkey, 3 - 07 May 2017
- XXVI. **t790M MutaSyonu pozitif akciğer kanserinde oSiMERTiniB diREnci; olgu SunuMu**

- BİLGİN B., ŞENDUR M. A. N., HIZAL M., ŞENER DEDE D., AKINCI M. B., SILAY K., YALÇIN B.
22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017
- XXVII. **İLERİ EVRE KOLOREKTAL KANSERLERDE RDW-PLATELET ORANININ PROGNOSTİK ÖNEMİ**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., AKINCI M. B., YAMAN S., ULUTAŞ KANDİL S., ŞENER DEDE D., YALÇIN A., SILAY K., YALÇIN B.
22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017
- XXVIII. **Metastatik Olmayan Kolorektal Adenokanserlerde Lenf Nodu Metastazı İçin Prediktif Faktörlerin Değerlendirilmesi**
KARCI E., KÖKSOY E. B., HOCAZADE C., BİLGİN B., ALKAN A., TUNCAY G., YAŞAR H. A., ÜRÜN M., DOĞAN N., YILDIRIM N., et al.
22. Ulusal Kanser Kongresi, Turkey, 19 - 23 April 2017
- XXIX. **ERKEN EVRE KOLOREKTAL KANSERLERDE RDW-PLATELET ORANININ PROGNOSTİK ÖNEMİ**
BİLGİN B., HIZAL M., AKINCI M. B., ŞENDUR M. A. N., ŞENER DEDE D., ÖZDEMİR N., YAMAN S., ULUTAŞ KANDİL S., YALÇIN A., KILIÇ M., et al.
22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017
- XXX. **2016 YILINDA TÜRKİYE KAYNAKLI ONKOLOJİK YAYINLAR**
ŞENDUR M. A. N., BİLGİN B., HIZAL M., ÖZDEMİR N., AKINCI M. B., ŞENER DEDE D., YAZICI O., SILAY K., ZENGİN N., YALÇIN B.
22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017
- XXXI. **Prognostic importance red cell disturbance width to platelet ratio in advanced colorectal cancer**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., AKINCI M. B., YAMAN S., ULUTAŞ S. K., ÖZDEMİR N., ŞENER DEDE D., YALÇIN A., YALÇIN B.
6th international Gastrointestinal cancer conference December 2016 Antalya, Turkey, 2 November - 06 December 2016
- XXXII. **THE PROGNOSTIC FACTORS IN STAGE 3 COLORECTAL CANCER PATIENTS**
HIZAL M., BİLGİN B., ŞENDUR M. A. N., AKINCI M. B., ŞENER DEDE D., YAMAN S., KANDİL S. U., YALÇIN A., KILIÇ M., YALÇIN B.
6th International Gastrointestinal Cancer Conference, 2 - 04 December 2016
- XXXIII. **THE NEUTROPHIL LYMPHOCYTE RATIO MAY HAVE PROGNOSTIC EFFECT IN THE METASTATIC COLORECTAL CANCER**
HIZAL M., BİLGİN B., ŞENDUR M. A. N., DEDİ D. Ş., AKINCI M. B., KANDİL S. U., YAMAN S., YALÇIN A., YALÇIN B.
6th International Gastrointestinal Cancer Conference, 2 - 04 December 2016
- XXXIV. **PROGNOSTIC IMPORTANCE RED CELL DISTURBATION WIDTH TO PLATELET RATIO IN ADVANCED COLORECTAL CANCER**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., AKINCI M. B., YAMAN S., KANDİL S. U., ÖZDEMİR N. Y., ŞENER DEDE D., YALÇIN A., YALÇIN B.
6th International Gastrointestinal Cancer Conference, 2 - 04 December 2016
- XXXV. **METASTATIC COLORECTAL CANCER SURVIVAL IS THERE A DIFFERENCE BETWEEN SYNCHRONOUS OR METACHRONOUS TUMORS**
HIZAL M., BİLGİN B., ŞENDUR M. A. N., DEDİ D. Ş., AKINCI M. B., YAMAN S., KANDİL S. U., YALÇIN A., KILIÇ M., YALÇIN B.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- XXXVI. **EFFECT OF THE RAS STATUS ON SURVIVAL IN ADVANCED COLON CANCER**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., KANDİL S. U., YAMAN S., AKINCI M. B., DEDİ D. Ş., ÖZDEMİR N. Y., YALÇIN A., YALÇIN B.
6th International Gastrointestinal Cancer Conference, 2 - 04 December 2016
- XXXVII. **A rare case metastatic anal cloacogenic transitional cell carcinoma**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., AKINCI M. B., YAMAN S., ULUTAŞ KANDİL S., ŞENER DEDE D., YALÇIN B.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- XXXVIII. **Association between tumor localisation and clinicopathological characteristics and survival of colorectal cancer**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., ŞENER DEDE D., AKINCI M. B., YAMAN S., ULUTAŞ KANDİL S., ÖZDEMİR N., KILIÇ

- M., YALÇIN B.
th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- XXXIX. **Compare tumor features and survival in right sided and left sided early stage colorectal cancer**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., ŞENER DEDE D., AKINCI M. B., ÖZDEMİR N., Yaman S., Ulutaş Kandil S., KILIÇ M., YALÇIN B.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- XL. **ASSOCIATION BETWEEN TUMOR LOCALISATION AND CLINICOPATHOLOGICAL CHARACTERISTICS AND SURVIVAL OF COLORECTAL CANCER**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., ŞENER DEDE D., AKINCI M. B., yaman s., ulutaş kandil s., ÖZDEMİR N., KILIÇ M., YALÇIN B.
6,International gastrointestinal cancer confrence, 2 - 04 December 2016
- XLI. **ASSESSMENT OF THE COST EFFECTIVENESS OF THE FIRST LINE TARGETED THERAPIES FOR ADVANCED COLON CANCER IN TURKEY**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., ŞENER DEDE D., ulutaş kandil s., yaman s., AKINCI M. B., YALÇIN B.
6,International gastrointestinal cancer confrence, 2 - 04 December 2016
- XLII. **Effects of neutrophil lymphocyte ratio and platelet lymphocyte ratio on survival of non metastatic colorectal cancer**
HIZAL M., BİLGİN B., ŞENDUR M. A. N., AKINCI M. B., ŞENER DEDE D., Ulutaş Kandil S., yaman S., KILIÇ M., YALÇIN B.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- XLIII. **Metastatic colorectal cancer survival Is there a difference between synchronous or metachronous tumors**
HIZAL M., BİLGİN B., ŞENDUR M. A. N., ŞENER DEDE D., AKINCI M. B., yaman s., Ulutaş Kandil S., YALÇIN A., KILIÇ M., YALÇIN B.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- XLIV. **Gastric cancer with lung metastasis and concurrent miliary tuberculosis**
HIZAL M., BİLGİN B., ŞENDUR M. A. N., AKINCI M. B., ŞENER DEDE D., YALÇIN B.
6th International Gastrointestinal Cancers Conference, 2 - 04 December 2016
- XLV. **Effect of using different antihypertensive drugs ondemographic and clinico pathological characteristics ofbreast cancer** M A Sendur1 S Aksoy2 N Ozdemir1 O Yazici3 M B Akinci1 D S Dede1 B Yalçin1 N Zengin1 K Altundag2
ŞENDUR M. A. N., AKSOY S., ÖZDEMİR N., YAZICI O., AKINCI M. B., ŞENER DEDE D., YALÇIN B., ZENGİN N., ALTUNDAĞ M. K.
ESMO, 7 - 11 November 2016
- XLVI. **Hodgkin lenfomada PD-1, PD-L1 eksresyonunun EBV (Ebstein Barr Virus) ile ilişkisi ve prognostik önemi**
ÖZTÜRK V., TATLI DOĞAN H., BALCI S., SÜNGÜ N., BAKANAY ÖZTÜRK Ş. M., ŞENTÜRK YIKILMAZ A., ŞENER DEDE D., YALÇIN B., KILIÇARSLAN A.
26. Ulusal Patoloji 7. Ulusal Sitopatoloji Kongresi, Turkey, 2 - 06 November 2016
- XLVII. **Effect of red cell disturbation width to platelet ratio on disease free survival in early stage colorectal cancer**
BİLGİN B., HIZAL M., AKINCI M. B., ŞENDUR M. A. N., ŞENER DEDE D., ÖZDEMİR N., YAMAN S., ULUTAŞ KANDİL S., YALÇIN A., YALÇIN B.
6th international Gastrointestinal cancer confrence December 2016 Antalya, Turkey, 2 - 06 November 2016
- XLVIII. **HODGKİN LENFOMADA PD-1, PD-L1 EKSPRESYONUNUN EBV (EPSTEİN-BARR VİRUS) İLE İLİŞKİSİ VE PROGNOSTİK ÖNEMİ**
öztürk v., TATLI DOĞAN H., BALCI S., SÜNGÜ N., BAKANAY ÖZTÜRK Ş. M., ŞENTÜRK YIKILMAZ A., ŞENER DEDE D., YALÇIN B., KILIÇARSLAN A.
26. ULUSAL PATOLOJİ 7. ULUSAL SİTOPATOLOJİ KONGRESİ, Turkey, 2 - 06 November 2016
- XLIX. **Association between tumor localisation andClinicopathologic characteristics and survival of colorectal cancer**
BİLGİN B., HIZAL M., ŞENDUR M. A. N., ŞENER DEDE D., AKINCI M. B., YAMAN S., ULUTAS KANDİL S., ÖZDEMİR N.,

KILIÇ M., YALÇIN B.

6th international Gastrointestinal cancer conference December 2016 Antalya, Turkey, 2 - 06 November 2016

- L. **Efficacy of statin usage before diagnosis on clinico pathological characteristics and outcome of invasive breast cancer** *Annals of Oncology*
ŞENDUR M. A. N., AKSOY S., ÖZDEMİR N., yazıcı o., YALÇIN B., ZENGİN N., ALTUNDAĞ M. K.
41st ESMO Congress (ESMO 2016), 7 - 11 October 2016
- LI. **METASTATİK KOLON KANSERİ HASTALARINDA BİRİNCİ BASAMAK HEDEFE YÖNELİK TEDAVİLERİN MALİYET ANALİZİ**
BİLGİN B., ŞENDUR M. A. N., AKINCI M. B., ULAŞ A., YAMAN S., BAŞER S., YALÇIN B.
6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 - 27 March 2016
- LII. **METASTATİK MALİGN MELANOMDA BİRİNCİ BASAMAK TEDAVİLERİN MALİYET ANALİZİ**
BİLGİN B., ŞENDUR M. A. N., AKINCI M. B., ŞENER DEDE D., ULAŞ A., YAMAN S., BAŞER S., YALÇIN B.
6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 - 27 March 2016
- LIII. **The efficacy and predictive factors of response of second line triplet modified EOX epirubicin oxaliplatin capecitabine regimen in metastatic gastric cancer**
ŞENDUR M. A. N., ÖZDEMİR N., AKSOY S., yazıcı o., yazılıtaş d., AKINCI M. B., ŞENER DEDE D., YALÇIN B., ZENGİN N.
ESMO European Cancer Congress, 25 - 29 September 2015
- LIV. **Turkish National Breast Cancer Registry**
ALTUNDAĞ M. K., dumanlı e., aliustaoğlu m., uncu d., ÖZKAN M., ÇİÇİN İ., COŞKUN U., ELKIRAN E. T., KOÇER M., İŞIKDOĞAN A., et al.
asco annual meeting, 30 May - 03 June 2015
- LV. **Association of obesity with breast cancer clinical and pathological factors Analysis of Turkish National Breast Cancer Registry**
COŞKUN U., ALTUNDAĞ M. K., aliustaoğlu m., uncu d., ÖZKAN M., ÇİÇİN İ., ÇİLTAŞ A., ELKIRAN E. T., KOÇER M., İŞIKDOĞAN A., et al.
asco annual meeting, 30 May - 03 June 2015
- LVI. **Tissue Factor Gene 603A G and 5466A G polymorphisms are not Associated with Venous Thromboembolism in Cancer Patients**
EROĞLU A., GÜLEÇ CEYLAN G., öztürk e., KARASOY D., YALÇIN A., YALÇIN B., akar n.
Congress on Controversies in Thrombosis&Hemostasis, 30 October - 01 November 2014
- LVII. **The Prevalence and Clinical Significance of Serum Anti Cyclic Citrullinated Peptide Antibodies in Primary Sjögren's Syndrome**
AKTAN KÖŞKER T., ERTEN Ş., KÜÇÜKŞAHİN O., ALTUNOĞLU A., UZ E., YALÇIN B.
Mediterranean Congress of Rheumatology, 28 - 31 August 2014
- LVIII. **ASSESSMENT OF GERIATRIC SYNDROMES AND FUNCTIONAL STATUS IN ELDERLY HEMATOLOGIC CANCER PATIENTS IN TURKEY**
SILAY K., AKINCI M. B., GÜNEY T., ÖZTÜRK E., CANBAZ M., YALÇIN B., DİLEK İ.
19TH EHA (EUROPEAN HEMATOLOGY ASSOCIATION) CONGRESS 2014, 15 June 2014
- LIX. **Kronik Böbrek Hastalarında Serum Tiroid Uyarıcı Hormon'un (TSH) Diurnal Değişimi ve Bu Değişimin Tiroid Fonksiyonları Üzerine Etkisi**
SOYLU H., ERSOY R., BAL KESKE P., ERGİN M., ATEŞ C., ÇAKIR B., YALÇIN B.
36. Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi, Turkey, 21 May 2014
- LX. **Primary thyroid lymphoma Diagnosed during Pregnancy Report of a Case**
DEMİR ÖNAL E., POLAT Ş. B., KORKMAZ M. H., YALÇIN B., KÖYBAŞIOĞLU F., ERSOY R., ÇAKIR B.
15 th International & 14 th European Congress of Endocrinology, 5 - 09 May 2012
- LXI. **Gebelikte tiroidde ani büyüme ve bası semptomları ile kendini gösteren agresif B hücreli nonhodgkin lenfoma**
DEMİR ÖNAL E., POLAT Ş. B., KORKMAZ M. H., YALÇIN B., KÖYBAŞIOĞLU F., ERSOY R., ÇAKIR B.
33. Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi, Turkey, 12 - 16 October 2011
- LXII. **FLOW CYTOMETRY COMBINED WITH FINE NEEDLE ASPIRATION BIOPSY IS ESSENTIAL FOR DIAGNOSIS OF A RAPIDLY GROWING THYROID GLAND**

EVİRANOS B., AĐBAHT K., Atlı T., YALĐIN B., ERDOĐAN M. F.

34th Annual Meeting of the European Thyroid Association, 5 - 09 September 2009

Supported Projects

YALĐIN B., Project Supported by Higher Education Institutions, Makale Destek, 2015 - 2016

YALĐIN B., Project Supported by Higher Education Institutions, Kanseri olgularda venöz tromboembolizm gelişiminde koagülasyon faktör III (doku faktörü, DF) geninde -603A/G ve +5466A>G polimorfizmlerin etkinliğinin araştırılması, 2013 - 2015

Metrics

Publication: 162

Citation (WoS): 65

Citation (Scopus): 540

H-Index (WoS): 4

H-Index (Scopus): 11

Non Academic Experience

Ankara Üniversitesi Tıp Fakültesi

Ankara Altındağ Belediyesi Sağlık müdürlüğü

Ankara Üniversitesi Tıp Fakültesi